Nasdaq
Government Contracts & Awards
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
Looking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.
Review & Preview: Big Tech’s $889 Billion Reality Check
The market’s nonchalance over escalations in Iran came to an abrupt end on Thursday, as oil prices settled above $100 a barrel for the first time in two months. Ongoing jitters about hyperscalers spending too much on the AI buildout weren’t helping matters, and the combination of those factors wiped out hundreds of billions of dollars in market cap. The Nasdaq Composite sank 2.1%.
Wall St falls as tech earnings spark AI spending worries
STORY: Wall Street stocks plummeted on Thursday, with the Dow dropping about 1%, the S&P 500 shedding 1.2% and the Nasdaq tumbling more than 2%.The latest earnings results from large tech companies such as Alphabet and Tesla revived concerns about heavy AI spending, says Keith Buchanan, senior portfolio manager for Globalt Investments."We're at a point now where the hype has to kind of meet some level of realistic expectation, quantifiable expectation. And the markets are starting to digest just what this means to cash flow in some of the largest companies in the world going forward. And a lot of spending is eating into cash flow in a way that's making investors lose a bit of comfort and question a lot of valuations that have grown over the past couple of years. And that's what's really at the root of what's really hampering some of the market returns today and giving back some of the gains that we've gotten for the market over the past couple of weeks."Shares of Alphabet sank 7% after
S&P 500, Dow, Nasdaq End Lower Over Capex Concerns, Surging Oil — CBRS, AMD, GOOGL, TSLA, MSTR In Focus
Brent crude topped $100 a barrel, stoking inflation fears and driving Treasury yields to their highest levels of the year.
Cerebras Systems (CBRS) Teams Up With CrowdStrike To Push AI Cybersecurity
Cerebras Systems (NasdaqGS:CBRS) and CrowdStrike announced a partnership to combine Cerebras AI accelerator hardware with the CrowdStrike Falcon AI cybersecurity platform. The alliance includes CrowdStrike using Cerebras chips for its core security offering, while Cerebras adopts Falcon AI to protect its own infrastructure. The collaboration focuses on real-time, AI-driven enterprise security, targeting growing demand in cybersecurity workloads. Cerebras Systems enters this partnership with...
Dow Jones Futures: Market Sells Off On Oil Prices, Google, Tesla; Intel Jumps Late, SpaceX Starship Launch Due
The Nasdaq undercut key levels as Google and Tesla led titans lower while oil prices soared. A big SpaceX launch is due.
Update: Nasdaq, S&P 500 Log Worst Day in More Than Four Weeks as Brent Tops $100
(Updates with market moves at the end of the day.) The Nasdaq Composite and the S&P 500 fell the
GE HealthCare announces CFO transition; reports preliminary second quarter 2026 financial results and reaffirms guidance reflecting business momentum
CHICAGO, July 23, 2026--GE HealthCare (Nasdaq: GEHC) today announced that Jay Saccaro will step down as Vice President and Chief Financial Officer for an expanded role outside of the medical technology industry. The Company has appointed George Newcomb, currently Controller and Chief Accounting Officer, as interim Chief Financial Officer. Mr. Saccaro will remain with the Company through August 14, 2026, and work together with Mr. Newcomb to ensure a smooth transition. GE HealthCare has commenced
AI Jitters and Oil Fears Send Stocks Reeling
A selloff in Big Tech stocks and rising oil prices drowned the major indexes on Thursday. The Nasdaq sank 2.1%. The Dow fell 507 points, or 1%. The S&P 500 dropped 1.2%. Alphabet and Tesla both fell sharply after their kickoff to Magnificent Sevens earnings season rekindled broader market worries about companies spending big on artificial intelligence.
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Media Release COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigato
Congressional Trades in $NDAQ
Insider Trades (Form 4)
No Form 4 insider trades found for $NDAQ.
Key People
No individuals linked to this entity yet.
Political Giving
$92,000 given to 18 candidates across 45 disclosed contributions (FEC Schedule A).
James French Hill
Ann Wagner
Ritchie John Torres
Bill Hagerty
Daniel Meuser
Vicente Gonzalez
Brad Sherman
Katherine M. Clark
Ted Cruz
Cynthia Lummis
Warren Davidson
Sean Casten
Josh Gottheimer
Max Miller
Stephanie Bice
Nicole Malliotakis
Byron Donalds
Doris O. Matsui
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro